Eli Lilly agreed to acquire AtaiBeckley in a deal valuing the upfront consideration at $2.8 billion, with additional milestone-related contingent value rights that could raise total consideration to about $3.8 billion. The acquisition targets AtaiBeckley’s intranasal psychedelic candidate BPL-003 for treatment-resistant depression, currently in pivotal testing.